Objectives
Marburg virus (MbVs), which causes Marburg viral disease (MbVD), primarily manifests flu-like symptoms, but critical hemorrhagic fever appears toward the end. It transmits through direct contact between individuals or animals. While incidences may be rare, the elevated mortality rate of this virus is a significant concern. Currently, there is no vaccine for this lethal virus. Immunization is essential for reducing the mortality rate associated with this disease. We recommend employing immunoinformatics techniques and MbV structural proteins to develop multi-epitope vaccine.
Methods
A multi-epitope vaccine was created using B-cell and T-cell epitopes of MbV, along with adjuvants and specific linkers. The proposed vaccine was assessed for antigenicity, allergenicity, toxicity, and population coverage. Additionally, in silico immune response models were conducted. The vaccine design was further analyzed for expression and cloning viability utilizing the pET-28a(+) vector.
Results
The designed vaccine exhibited antigenic, non-allergenic, and non-toxic properties. It demonstrated excellent global population coverage and induced a robust immune response in silico. Furthermore, the in silico assessments confirmed the effective expression and cloning of the vaccine in E. coli, indicating its feasibility for large-scale manufacturing in the pharmaceutical industry.
Conclusion
The results suggest that the proposed vaccine design may effectively elicit immune responses against MbV. Future studies must incorporate in vivo testing to validate these findings.
扫码关注我们
求助内容:
应助结果提醒方式:
